Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Evotec invests $18 million in Exscientia
by Ryan Cross
October 9, 2017
| A version of this story appeared in
Volume 95, Issue 40
The German contract research firm Evotec is expanding a partnership with the AI-based drug discoverer Exscientia and acquiring an $18 million stake in the company. Evotec’s collaboration with the British firm began 18 months ago to design immuno-oncology drugs that purposefully bind two targets. Evotec CEO Werner Lanthaler liked what he saw. The new deal makes the two firms 50:50 partners on their drug discovery program, Lanthaler says, adding that it is unlikely Evotec would take a compound to the clinic alone.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X